
Sign up to save your podcasts
Or


AI has the potential to revolutionize clinical trials in many ways. It could make the development of new treatments faster, safer, cheaper and more personalised. One company in this space is Owkin, a unicorn startup based in Paris. With me is Dr Félix Balazard, Director of
By Dr. Felix Beacher4
44 ratings
AI has the potential to revolutionize clinical trials in many ways. It could make the development of new treatments faster, safer, cheaper and more personalised. One company in this space is Owkin, a unicorn startup based in Paris. With me is Dr Félix Balazard, Director of

318 Listeners

1,101 Listeners

304 Listeners

341 Listeners

236 Listeners

209 Listeners

306 Listeners

106 Listeners

56 Listeners

209 Listeners

588 Listeners

268 Listeners

108 Listeners

61 Listeners

46 Listeners